Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last521 to 540 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Use for Children With Acute Otitis Media | 6,154 of 9,020 6,287 of 7,778 | -12.6 points -13.9 to -11.3 | 16,798 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Duration for Pediatric Acute Otitis Media | 7,565 of 9,020 7,281 of 7,778 | -9.7 points -10.7 to -8.8 | 16,798 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Bococizumab (PF-04950615) vs Placebo: deaths from any cause | 72 of 8,386 65 of 8,374 | 0.1 points -0.2 to 0.4 | 16,760 | NCT01975376 The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects |
| Bococizumab (PF-04950615) vs Placebo: serious adverse events | 1,060 of 8,386 986 of 8,374 | 0.9 points -0.1 to 1.9 | 16,760 | NCT01975376 The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects |
| Home Assessment and Initiation of ART vs Clinic-based ART Assessment and Initiation: Reporting of HIV-positive Results | 490 of 8,194 278 of 8,466 | 2.7 points 2.1 to 3.3 | 16,660 | NCT01414413 Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi |
| Home Assessment and Initiation of ART vs Clinic-based ART Assessment and Initiation: Uptake of Home-based HIV Testing | 5,287 of 8,194 4,433 of 8,466 | 12.2 points 10.7 to 13.6 | 16,660 | NCT01414413 Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi |
| Home Assessment and Initiation of ART vs Clinic-based ART Assessment and Initiation: ART Initiation | 181 of 8,194 63 of 8,466 | 1.5 points 1.1 to 1.8 | 16,660 | NCT01414413 Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi |
| Saxagliptin vs Placebo: Participants With Event of Death | 420 of 8,280 378 of 8,212 | 0.5 points -0.2 to 1.1 | 16,492 | NCT01107886 Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications |
| Saxagliptin vs Placebo: Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke | 613 of 8,280 609 of 8,212 | -0.0 points -0.8 to 0.8 | 16,492 | NCT01107886 Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications |
| Saxagliptin vs Placebo: Participants With Any Event From the Composite of CV Death, Non-fatal MI, Non-fatal Ischaemic Stroke, Hospitalisation for Heart Failure, Hospitalisation for Unstable Angina Pectoris, or Hospitalisation for Coronary Revascularisation | 1,059 of 8,280 1,034 of 8,212 | 0.2 points -0.8 to 1.2 | 16,492 | NCT01107886 Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications |
| Saxagliptin vs Placebo: serious adverse events | 2,114 of 8,280 2,075 of 8,212 | 0.3 points -1.1 to 1.6 | 16,492 | NCT01107886 Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications |
| Women Who Enrolled in EAQ201 vs Women Who Enrolled in TMIST: Compare the Proportion of WOC in TMIST Participants vs EAQ201 Participants | 1 of 14 1,138 of 16,427 | 0.2 points -5.7 to 24.5 | 16,441 | NCT05076266 COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation |
| ARCT-154 vs Placebo: Number of Participants With a First Occurrence of COVID-19 Irrespective of Prior Infection | 223 of 8,492 457 of 7,941 | -3.1 points -3.8 to -2.5 | 16,433 | NCT05012943 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) |
| ARCT-154 vs Placebo: Number of Participants With Death Due to COVID-19 | 1 of 8,492 9 of 7,940 | -0.1 points -0.2 to -0.0 | 16,432 | NCT05012943 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) |
| ARCT-154 vs Placebo: Number of Participants With a First Occurrence of Severe COVID-19 | 2 of 8,492 43 of 7,940 | -0.5 points -0.7 to -0.4 | 16,432 | NCT05012943 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) |
| Vaccine vs Placebo: deaths from any cause | 85 of 8,197 75 of 8,198 | 0.1 points -0.2 to 0.4 | 16,395 | NCT00223080 HIV Vaccine Trial in Thai Adults |
| Vaccine vs Placebo: serious adverse events | 1,175 of 8,197 1,219 of 8,198 | -0.5 points -1.6 to 0.5 | 16,395 | NCT00223080 HIV Vaccine Trial in Thai Adults |
| Clostridium Difficile Vaccine vs Placebo: Number of Participants With Recurrent Episodes of CDI (Definition 2) After Dose 2 | 6 of 8,139 3 of 8,184 | 0.0 points -0.0 to 0.1 | 16,323 | NCT03090191 Clostridium Difficile Vaccine Efficacy Trial |
| Clostridium Difficile Vaccine vs Placebo: Number of Participants With Recurrent Episode of CDI (Definition 2) After Dose 2 and Before Dose 3 | 1 of 8,139 0 of 8,184 | 0.0 points -0.0 to 0.1 | 16,323 | NCT03090191 Clostridium Difficile Vaccine Efficacy Trial |
| No PN Use (Project B) vs PN Use (Project B): Necrotising Enterocolitis (Project B) | 285 of 8,146 660 of 8,146 | -4.6 points -5.3 to -3.9 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=27
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT06027593-bb375b40",
"title": "Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Use for Children With Acute Otitis Media",
"summary": "6154 of 9020 against 6287 of 7778; risk difference -12.6 points, 95% interval -13.9 to -11.3; NCT06027593, Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions",
"record": "/library/comparisons/NCT06027593-bb375b40",
"nct_id": "NCT06027593",
"kind": "outcome",
"participants": 16798,
"risk_difference": {
"value": -0.12604383618814563,
"lower": -0.13899217185517027,
"upper": -0.1130053205072896
},
"group_1": "6,154 of 9,020",
"group_2": "6,287 of 7,778",
"difference": "-12.6 points",
"interval": "-13.9 to -11.3",
"trial_title": "Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions"
},
{
"id": "NCT06027593-cf5d5b37",
"title": "Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Duration for Pediatric Acute Otitis Media",
"summary": "7565 of 9020 against 7281 of 7778; risk difference -9.7 points, 95% interval -10.7 to -8.8; NCT06027593, Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions",
"record": "/library/comparisons/NCT06027593-cf5d5b37",
"nct_id": "NCT06027593",
"kind": "outcome",
"participants": 16798,
"risk_difference": {
"value": -0.09741002965325474,
"lower": -0.10674283098324994,
"upper": -0.08806088279567512
},
"group_1": "7,565 of 9,020",
"group_2": "7,281 of 7,778",
"difference": "-9.7 points",
"interval": "-10.7 to -8.8",
"trial_title": "Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=28",
"request_id": "misPjIbvvf1EhOpz"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant